User menu

Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy

Bibliographic reference Van Cutsem, Eric ; Joulain, Florence ; Hoff, Paulo M ; Mitchell, Edith ; Ruff, Paul ; et. al. Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy. In: Targeted Oncology : biotherapies for the clinicians in oncology, Vol. 11, no.3, p. 383-400 (2015)
Permanent URL http://hdl.handle.net/2078.1/184179
  1. Hurwitz Herbert, Fehrenbacher Louis, Novotny William, Cartwright Thomas, Hainsworth John, Heim William, Berlin Jordan, Baron Ari, Griffing Susan, Holmgren Eric, Ferrara Napoleone, Fyfe Gwen, Rogers Beth, Ross Robert, Kabbinavar Fairooz, Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer, 10.1056/nejmoa032691
  2. Escudier Bernard, Pluzanska Anna, Koralewski Piotr, Ravaud Alain, Bracarda Sergio, Szczylik Cezary, Chevreau Christine, Filipek Marek, Melichar Bohuslav, Bajetta Emilio, Gorbunova Vera, Bay Jacques-Olivier, Bodrogi Istvan, Jagiello-Gruszfeld Agnieszka, Moore Nicola, Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial, 10.1016/s0140-6736(07)61904-7
  3. Giantonio Bruce J., Catalano Paul J., Meropol Neal J., O'Dwyer Peter J., Mitchell Edith P., Alberts Steven R., Schwartz Michael A., Benson Al B., Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200, 10.1200/jco.2006.09.6305
  4. Van Cutsem Eric, Tabernero Josep, Lakomy Radek, Prenen Hans, Prausová Jana, Macarulla Teresa, Ruff Paul, van Hazel Guy A., Moiseyenko Vladimir, Ferry David, McKendrick Joe, Polikoff Jonathan, Tellier Alexia, Castan Rémi, Allegra Carmen, Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen, 10.1200/jco.2012.42.8201
  5. Sandler Alan, Gray Robert, Perry Michael C., Brahmer Julie, Schiller Joan H., Dowlati Afshin, Lilenbaum Rogerio, Johnson David H., Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer, 10.1056/nejmoa061884
  6. Rini Brian I., Halabi Susan, Rosenberg Jonathan E., Stadler Walter M., Vaena Daniel A., Archer Laura, Atkins James N., Picus Joel, Czaykowski Piotr, Dutcher Janice, Small Eric J., Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206, 10.1200/jco.2009.26.5561
  7. Gil-Gil Miguel J., Mesia Carlos, Rey Montserrat, Bruna Jordi, Bevacizumab for the Treatment of Glioblastoma, 10.4137/cmo.s8503
  8. Ciombor K. K., Berlin J., Chan E., Aflibercept, 10.1158/1078-0432.ccr-12-2911
  9. Holash J., Davis S., Papadopoulos N., Croll S. D., Ho L., Russell M., Boland P., Leidich R., Hylton D., Burova E., Ioffe E., Huang T., Radziejewski C., Bailey K., Fandl J. P., Daly T., Wiegand S. J., Yancopoulos G. D., Rudge J. S., VEGF-Trap: A VEGF blocker with potent antitumor effects, 10.1073/pnas.172398299
  10. Papadopoulos Nicholas, Martin Joel, Ruan Qin, Rafique Ashique, Rosconi Michael P., Shi Ergang, Pyles Erica A., Yancopoulos George D., Stahl Neil, Wiegand Stanley J., Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab, 10.1007/s10456-011-9249-6
  11. Carmeliet Peter, Moons Lieve, Luttun Aernout, Vincenti Valeria, Compernolle Veerle, De Mol Maria, Wu Yan, Bono Françoise, Devy Laetitia, Beck Heike, Scholz Dimitri, Acker Till, DiPalma Tina, Dewerchin Mieke, Noel Agnes, Stalmans Ingeborg, Barra Adriano, Blacher Sylvia, Vandendriessche Thierry, Ponten Annica, Eriksson Ulf, Plate Karl H., Foidart Jean-Michel, Schaper Wolfgang, Charnock-Jones D. Stephen, Hicklin Daniel J., Herbert Jean-Marc, Collen Désiré, Persico M. Graziella, 10.1038/87904
  12. Lieu CH, Tran H, Jiang ZQ, Mao M, Overman MJ, Lin E, Eng C, Morris J, Ellis L, Heymach JV, Kopetz S (2013) The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer. PLoS One 8: e77117
  13. Fan F, Samuel S, Gaur P, Lu J, Dallas N A, Xia L, Bose D, Ramachandran V, Ellis L M, Chronic exposure of colorectal cancer cells to bevacizumab promotes compensatory pathways that mediate tumour cell migration, 10.1038/bjc.2011.81
  14. Tabernero Josep, Van Cutsem Eric, Lakomý Radek, Prausová Jana, Ruff Paul, van Hazel Guy A., Moiseyenko Vladimir M., Ferry David R., McKendrick Joseph J., Soussan-Lazard Karen, Chevalier Soazig, Allegra Carmen J., Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: Prespecified subgroup analyses from the VELOUR trial, 10.1016/j.ejca.2013.09.013
  15. O'Connell Michael J., Campbell Megan E., Goldberg Richard M., Grothey Axel, Seitz Jean-François, Benedetti Jacqueline K., André Thierry, Haller Daniel G., Sargent Daniel J., Survival Following Recurrence in Stage II and III Colon Cancer: Findings From the ACCENT Data Set, 10.1200/jco.2007.15.8261
  16. Chau Ian, Joulain Florence, Iqbal Sheikh Usman, Bridgewater John, A VELOUR post hoc subset analysis: prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRI, 10.1186/1471-2407-14-605
  17. Schmoll H. J., Van Cutsem E., Stein A., Valentini V., Glimelius B., Haustermans K., Nordlinger B., van de Velde C. J., Balmana J., Regula J., Nagtegaal I. D., Beets-Tan R. G., Arnold D., Ciardiello F., Hoff P., Kerr D., Kohne C. H., Labianca R., Price T., Scheithauer W., Sobrero A., Tabernero J., Aderka D., Barroso S., Bodoky G., Douillard J. Y., El Ghazaly H., Gallardo J., Garin A., Glynne-Jones R., Jordan K., Meshcheryakov A., Papamichail D., Pfeiffer P., Souglakos I., Turhal S., Cervantes A., ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making, 10.1093/annonc/mds236
  18. Bennouna Jaafar, Sastre Javier, Arnold Dirk, Österlund Pia, Greil Richard, Van Cutsem Eric, von Moos Roger, Viéitez Jose Maria, Bouché Olivier, Borg Christophe, Steffens Claus-Christoph, Alonso-Orduña Vicente, Schlichting Christoph, Reyes-Rivera Irmarie, Bendahmane Belguendouz, André Thierry, Kubicka Stefan, Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial, 10.1016/s1470-2045(12)70477-1
  19. Kaplan E. L., Meier Paul, Nonparametric Estimation from Incomplete Observations, 10.1080/01621459.1958.10501452
  20. Van Cutsem Eric, Lambrechts Diether, Prenen Hans, Jain Rakesh K., Carmeliet Peter, Lessons From the Adjuvant Bevacizumab Trial on Colon Cancer: What Next?, 10.1200/jco.2010.32.2701
  21. Ruff Paul, Ferry David R., Lakomỳ Radek, Prausová Jana, Van Hazel Guy A., Hoff Paulo M., Cunningham David, Arnold Dirk, Schmoll Hans J., Moiseyenko Vladimir M., McKendrick Joseph J., ten Tije Albert J., Vishwanath Raghu L., Bhargava Pankaj, Chevalier Soazig, Macarulla Teresa, Van Cutsem Eric, Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy, 10.1016/j.ejca.2014.10.019
  22. Masi G., Salvatore L., Boni L., Loupakis F., Cremolini C., Fornaro L., Schirripa M., Cupini S., Barbara C., Safina V., Granetto C., Fea E., Antonuzzo L., Boni C., Allegrini G., Chiara S., Amoroso D., Bonetti A., Falcone A., Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial, 10.1093/annonc/mdv012
  23. Tabernero Josep, Yoshino Takayuki, Cohn Allen Lee, Obermannova Radka, Bodoky Gyorgy, Garcia-Carbonero Rocio, Ciuleanu Tudor-Eliade, Portnoy David C, Van Cutsem Eric, Grothey Axel, Prausová Jana, Garcia-Alfonso Pilar, Yamazaki Kentaro, Clingan Philip R, Lonardi Sara, Kim Tae Won, Simms Lorinda, Chang Shao-Chun, Nasroulah Federico, Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study, 10.1016/s1470-2045(15)70127-0
  24. Osterlund P, Alonso-Orduna V, Schlichting C, Andre T, Sastre J, Greil R, Kubicka S, Reyes-Rivera I, McCall B, Van Cutsem E (2012) Bevacizumab plus chemotherapy beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with first-line bevacizumab plus chemotherapy (ML18147): efficacy and safety analyses by oxaliplatin vs irinotecan-based CT. Ann Oncol 23 [Suppl 9]:195
  25. Bendell J. C., Bekaii-Saab T. S., Cohn A. L., Hurwitz H. I., Kozloff M., Tezcan H., Roach N., Mun Y., Fish S., Flick E. D., Dalal D., Grothey A., Treatment Patterns and Clinical Outcomes in Patients With Metastatic Colorectal Cancer Initially Treated with FOLFOX-Bevacizumab or FOLFIRI-Bevacizumab: Results From ARIES, a Bevacizumab Observational Cohort Study, 10.1634/theoncologist.2012-0190
  26. Grothey Axel, Sugrue Mary M., Purdie David M., Dong Wei, Sargent Daniel, Hedrick Eric, Kozloff Mark, Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE), 10.1200/jco.2008.16.3212
  27. Bibeau F, Gil H, Castan F, Boissière-Michot F, Comment on ‘Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab’, 10.1038/bjc.2013.651
  28. Chun Yun Shin, Association of Computed Tomography Morphologic Criteria With Pathologic Response and Survival in Patients Treated With Bevacizumab for Colorectal Liver Metastases, 10.1001/jama.2009.1755
  29. Loupakis F, Schirripa M, Caparello C, Funel N, Pollina L, Vasile E, Cremolini C, Salvatore L, Morvillo M, Antoniotti C, Marmorino F, Masi G, Falcone A, Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab, 10.1038/bjc.2013.245
  30. Chiron M., Bagley R. G., Pollard J., Henry C., Mankoo P., Vincent L., Geslin C., Kloss T., Bergstrom D. A., Abstract B2: Switching to aflibercept treatment resulted in greater tumor responses than continuous bevacizumab treatment in patient-derived xenograft models of colorectal cancer., 10.1158/1535-7163.targ-13-b2